Investigative Ophthalmology & Visual Science Cover Image for Volume 59, Issue 9
July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Retinal vascular fractal dimension as a marker of treatment-response in neovascular age-related macular degeneration
Author Affiliations & Notes
  • Thomas Lee Torp
    Department of Ophthalmology, Odense University Hospital , Odense, Denmark
    Department of Clinical Research, University of Southern Denmark, Odense, Region of Southern Denmark, Denmark
  • Ditte Borup Jakobsen
    Department of Ophthalmology, Odense University Hospital , Odense, Denmark
    Department of Clinical Research, University of Southern Denmark, Odense, Region of Southern Denmark, Denmark
  • Einar Stefansson
    Department of Ophthalmology, National Hospital Reykjavik, Reykjavik, Iceland
  • Tunde Peto
    School of Medicine, Dentistry and Biomedical Sciences , Queen’s University Belfast, Belfast, Ireland
    Department of Clinical Research, University of Southern Denmark, Odense, Region of Southern Denmark, Denmark
  • Jakob Grauslund
    Department of Ophthalmology, Odense University Hospital , Odense, Denmark
    Department of Clinical Research, University of Southern Denmark, Odense, Region of Southern Denmark, Denmark
  • Footnotes
    Commercial Relationships   Thomas Lee Torp, None; Ditte Jakobsen, None; Einar Stefansson, None; Tunde Peto, None; Jakob Grauslund, Bayer (S), Novartis (S)
  • Footnotes
    Support  The Velux Foundation
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 2376. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Thomas Lee Torp, Ditte Borup Jakobsen, Einar Stefansson, Tunde Peto, Jakob Grauslund; Retinal vascular fractal dimension as a marker of treatment-response in neovascular age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2018;59(9):2376.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Non-invasive structural retinal markers of disease activity are important to monitor treatment outcome in neovascular age-related macular degeneration (nAMD). We aimed to investigate if changes in the retinal vascular fractal dimension (FD) correlate with initial treatment outcome after intravitreal aflibercept therapy.

Methods : Fifty-seven eyes of 57 patients with treatment-naïve nAMD received three intravitreal injections with 2.0 mg aflibercept and were followed for three months (3M). Swept source optical coherence tomography (DRI OCT Triton, Topcon, Tokyo, Japan) and fluorescein and indocyanine green angiography (Spectralis, Heidelberg Engineering, Heidelberg, Germany) was performed to verify the diagnosis of nAMD. The FD was measured at baseline and 3M using the semi-automated software Fractal Analyzer (Singapore Institute Vessel Assessment-Fractal image analysis software, Singapore) according to a standardized grading-protocol. At 3M, the eyes were divided into full and partial responders. Partial responders were defined as loss of ≥5 Early Treatment Diabetic Retinopathy Study letters or residual retinal fluid or macular hemorrhage.

Results : At baseline, mean age was 79.4 years and 38.6% were male. Twenty nine point eight per cent were active smokers and 10.5% had diabetes. Twenty-six of 57 (45.6%) were full responders. These patients were older than partial responders (82.0 vs. 77.1 years, p=0.03), but did not differ at any time point according to sex, diabetes, smoking, intra ocular pressure, visual acuity or FD. In full responders, the FD decreased after treatment (1.5907 ±0.043 vs. 1.5714 ±0.0546, p=0.02), as opposed to partial responders (1.5877 ±0.037 vs. 1.577 ±0.041, p=0.07).

Conclusions : The retinal vascular fractal dimension decreases after initial loading with intravitreal aflibercept in fully-responding, treatment-naïve patients with nAMD. This indicates structural changes in the retinal vasculature and could be a guidance for individualized treatment if confirmed in long-term studies.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×